secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001193125-25-318488
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences appoints Keli Walbert to Board of Directors
--------------------------------------------------------------

- Keli Walbert appointed as Class I Director effective December 11, 2025, term expiring at 2027 annual meeting.
- Granted nonstatutory stock option to purchase 3,400 shares vesting monthly over three years.
- Annual cash retainer: $40,000 as director; $5,000 for Compensation Committee (increasing to $5,500 in 2026).
- Eligible for annual option grant of 1,700 shares starting with 2026 annual meeting, vesting over one year.
- Entered into standard indemnification agreement; no related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312525318488/0001193125-25-318488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312525318488/sprb-20251211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-318488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer